GentiBio is a clinical-stage company developing engineered Treg therapies to cure Type 1 diabetes and other autoimmune or acute inflammatory diseases
Our modular engineering platform creates optimized Tregs tailored for many autoimmune and inflammatory diseases
Innovative Treg Platform
We create T-regulatory cells (Tregs) engineered for specificity, stability, and survival that can succeed where the body’s Tregs have failed
Off-the-shelf Allogeneic Platform
Our proprietary immune-evasive engineering shields allogeneic Engineered Tregs from immune rejection and enable cost-of-goods comparable with biologics
Scalable Manufacturing
Our engineering platforms enable autologous and allogeneic approaches that can effectively supply large patient populations
GentiBio’s engineering augments Treg function and optimizes their manufacturing to create powerful and tailored therapeutics for autoimmune and inflammatory diseases
